#United States #New York #Gross Law Firm #class action lawsuit #Regeneron Pharmaceuticals

Gross Law Firm Urges Regeneron Investors to Take Action

On February 10, 2025, The Gross Law Firm issued an important notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This notice concerns a class action lawsuit set to impact investors who purchased share during a specific period. The legal firm encourages all affected shareholders to step forward and be aware of the impending deadlines involved in the case.

Class Period and Allegations

The complaints outlined in the case indicate significant allegations against Regeneron Pharmaceuticals. Shareholders who bought shares between November 2, 2023, and October 30, 2024, are encouraged to reach out and discuss potential lead plaintiff appointments. The essence of the allegations revolves around misleading statements made by the company's executives, which are said to have artificially inflated the company's stock prices.

Specifically, the claims assert that Regeneron engaged in practices that misrepresented the nature of its Eylea product sales. Several concerning points include:
1. Regeneron allegedly paid credit card fees to distributors, urging them not to charge Eylea customers additional fees when using credit cards.
2. These payments were purportedly used to subsidize costs for customers opting to purchase Eylea with credit cards, misleading them about the product's actual pricing.
3. By not disclosing these practices, Regeneron is accused of violating the False Claims Act, ultimately leading to a scenario where the reported Average Selling Price (ASP) to federal agencies was overstated.

With these revelations at the forefront, Regeneron is accused of misleading stakeholders about its sales performance. Such practices have raised serious ethical questions regarding corporate conduct and transparency.

Upcoming Deadlines

The deadline for shareholders wishing to seek lead plaintiff status is set for March 10, 2025. This is a crucial date for anyone looking to make their voice heard in the legal proceedings. Investors are advised not to delay their registration, as participating in this class action could lead to potential recovery for affected shareholders. Registration for the class action can be completed through the designated platform.

By getting involved, shareholders will gain access to ongoing portfolio monitoring tools that keep them updated on the case's developments, ensuring that they remain informed throughout the legal proceedings.

What to Expect Next

The Gross Law Firm is not only recognized as a crucial player in class action litigation but is dedicated to safeguarding the rights of investors. Their commitment involves ensuring that corporations uphold ethical business practices, respecting the rights of shareholders who may have suffered losses due to deceptive tactics.

For those who have suffered financial harm as a result of Regeneron’s actions, legal representation is available through The Gross Law Firm. Their approach emphasizes investor rights and seeks to hold companies accountable for their actions. There are no fees or obligations associated with participation in this case, making it accessible for all affected investors.

If you believe you may be eligible, it is highly recommended to reach out as soon as possible to denote your position as a shareholder. Participating in this case means taking an important step toward corporate accountability and investor justice.

Conclusion

As the implications of this lawsuit unfold, affected Regeneron shareholders should remain attentive to the developments and the fast-approaching deadlines. The Gross Law Firm stands ready to assist and provide guidance during this critical time, reinforcing the importance of investor rights amid complex corporate matters.